甲状腺髓样癌的辅助治疗

目的 评价放射治疗、化学治疗和放射性核素186Re对晚期甲状腺髓样癌的疗效。方法 回顾性分析本院1960年6月～2000年7月间接受放疗、化疗或放射性核素治疗的甲状腺髓样癌患者疗效。结果 放射治疗对术后肉眼残留者3年局控率为33．3％(3／9例)，对镜下残留者3年局控率达63．6％(7／11例)，单用放射治疗无效(3例)。化学治疗疗效不明显(11例)。放射性核素186Re对晚期甲状腺髓样癌肿瘤灶有抑制生长作用。结论 放射治疗对术后镜下残留、肉眼残留者不失为手术治疗的有益补充，能明显提高局控率。放射性核素186Re的治疗价值有待研究。

Adjuvant therapy for the medullary thyroid carcinoma

Objective To evaluate the efficacy of radiotherapy, chemotherapy and radionuclide 186 Re in the treatment of advanced medullary thyroid carcinoma. Methods The efficacy of patients with medullary thyroid carcinoma treated by radiation therapy,chemotherapy or radionuclide at this hospital from June 1960 to July 2000 was retrospectively analyzed. Results The 3-year local-controlled rates of radiation therapy for patients with postoperative naked-eye or microscopic residues were 33.3% (3 /9 cases) and 63.6%(7 /11 cases), respectively. Simple radio therapy or chemotherapy was uneffective. Radionuclide 186 Re can inhibit the growth of tumor for patients with advanced medullary thyroid carcinoma. Conclusion Radiotherapy was beneficial for patients with postoperative naked-eye or microscopic residues, and can improve local-controlled rate. The therapeutic effect of radionuclide 186 Re should be studied further.